ferric carboxymaltose (Rx)

Brand and Other Names:Injectafer
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 50 mg/mL (15-mL and 20-mL single-dose vials)
  • Each mL contains 50 mg of elemental iron

Iron Deficiency Anemia

Indicated for treatment of iron deficiency anemia (IDA) in adults who have intolerance or an unsatisfactory response to oral iron; also indicated for IDA in adults with nondialysis dependent chronic kidney disease

≥50 kg

  • 750 mg IV in 2 doses separated by at least 7 days; not to exceed cumulative dose of 1500 mg per course
  • Alternatively, may administer 15 mg/kg IV as a single dose; not to exceed 1000 mg

<50 kg

  • 15 mg/kg IV in 2 doses separated by at least 7 days
  • Not to exceed cumulative dose 1500 mg per course

Safety and efficacy not established

Next:

Adverse Effects

1-10%

Nausea (1-7.2%)

Injection site reactions (3-4%)

Hypertension (1-4%)

Flushing (0.3-4%)

Erythema (0.3-3%)

Dizziness (1-2.1%)

Hyperphosphatemia (1-2.1%)

Vomiting (0.2-2%)

Injection site extravasation (0.2-2%)

Injection site discoloration (<1.4%)

Headache (1-1.3%)

Hepatic enzyme increased (1.2%)

Rash (1-1.2%)

Dysgeusia (1-1.2%)

Hypotension (<1%)

<1%

Constipation (0.5%)

Postmarketing Reports

Cardiac disorders: Tachycardia

General disorders and administration site conditions: Chest discomfort, chills, pyrexia

Metabolism and nutrition disorders: Hypophosphatemia

Musculoskeletal and connective tissue disorders: Arthralgia, back pain, hypophosphatemic osteomalacia (rarely reported event)

Nervous system disorders: Syncope

Respiratory, thoracic and mediastinal disorders: Dyspnea

Skin and subcutaneous tissue disorders: Angioedema, erythema, pruritus, urticaria

Pregnancy: Fetal bradycardia

Previous
Next:

Warnings

Contraindications

Hypersensitivity

Cautions

Hypertension reported; transient elevations in systolic BP were observed and sometimes occurred with facial flushing, dizziness, or nausea; monitor patients for signs and symptoms of hypertension following the administration of the product

Laboratory assays may overestimate serum iron and transferrin bound iron in the 24 hr following administration

Hypophosphatemia

  • Symptomatic hypophosphatemia requiring clinical intervention has been reported in patients at risk of low serum phosphate in postmarketing setting; these cases have occurred mostly after repeated exposure to Injectafer in patients with no reported history of renal impairment
  • Possible risk factors for hypophosphatemia include a history of gastrointestinal disorders associated with malabsorption of fat-soluble vitamins or phosphate, concurrent or prior use of medications that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency and malnutrition; in most cases, hypophosphatemia resolved within three months

Serious hypersensitivity reactions

  • Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported
  • Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse
  • Monitor for signs and symptoms of hypersensitivity during and after administration for at least 30 minutes and until clinically stable following completion of the infusion
  • Only administer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions
Previous
Next:

Pregnancy & Lactation

Pregnancy

Data are insufficient to assess risk of major birth defects and miscarriage

Animal data

  • Administration of ferric carboxymaltose to rabbits during organogenesis caused adverse developmental outcomes including malformations and increased implantation loss at maternally toxic doses of ~12-23% of the human weekly dose of 750 mg (based on body surface area)

Clinical considerations

  • There are risks to mother and fetus associated with untreated IDA in pregnancy
  • Untreated IDA in pregnancy is associated with adverse maternal outcomes such as postpartum anemia; adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight
  • Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur, which may cause fetal bradycardia, especially during second and third trimester

Lactation

Available published data on use in lactating females demonstrate that iron is present in breast milk

Adverse reactions like constipation and diarrhea reported in the breastfed infants but not considered related to drug exposure

There is no information on effects on milk production

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin

Absorption

Peak plasma concentration: 37-333 mcg/mL

Peak plasma time: 0.25-1.21 hr

Distribution

Vd: 3 L

Elimination

Half-life: 7-12 hr

Renal elimination of iron was negligible

Previous
Next:

Administration

IV Compatibilities

0.9% NaCl

IV Preparation

Visually inspect vials for particulate matter and discoloration before administration; contains no preservatives

Each vial is intended for single-use only

Discard any unused drug remaining after injection

For IV infusion, dilute in up to 250 mL 0.9% NaCl; resulting concentration should be 2-4 mg/mL

IV Administration

IV infusion: Infuse over at least 15 minutes

IV push

  • 750-mg dose: Infuse over ~100 mg/min
  • 1000-mg dose: Infuse over 15 mg/min
  • Discard any unused portion

Extravasation

  • Avoid extravasation since brown discoloration of site may be long lasting
  • Monitor for extravasation; if extravasation occurs, discontinue administration at that site

Storage

Unopened vials

  • Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)
  • Do not freeze

Diluted solutions

  • Store at room temperature for 72 hr
  • Do not dilute to concentration less than 2 mg iron/mL to maintain physical and chemical stability
Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.